We serve Chemical Name:L-(3,3-2H2)Leucine CAS:362049-59-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:L-(3,3-2H2)Leucine
CAS.NO:362049-59-0
Synonyms:L-Leucine-3,3-d;L-(3,3-H)Leucine
Molecular Formula:C6H11D2NO2
Molecular Weight:133.185
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:225.8±23.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.463
PSA:63.32000
Exact Mass:133.107178
LogP:0.73
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like L-Leucine-3,3-d chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-(3,3-H)Leucine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Leucine-3,3-d Use and application,L-Leucine-3,3-d technical grade,usp/ep/jp grade.
Related News: There are limited treatment options for the disorder. Women with advanced endometrial cancer who are not candidates for curative therapy have a survival rate of just 17% Misch Metal, 99.0% min. rare earth content manufacturers In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion. Angiotensin II Antipeptide suppliers The Global Talent Visa, along with the High Potential Individual and Scale-up visa routes in the Innovation Strategy, provide fast-track visa routes for high skills individuals and their teams, attracting top research talent to the UK. 5-(morpholin-4-ylmethyl)-1,2-oxazole-3-carboxylic acid,hydrochloride vendor & factory He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. ,There are limited treatment options for the disorder. Women with advanced endometrial cancer who are not candidates for curative therapy have a survival rate of just 17%
